Authorization

Highlight Therapeutics announces first patient dosed in Phase IIa study in liver metastasis

MADRID, Spain, June 26, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the dosing of the first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.
Click on, or paste the following link into your web browser, to view the associated PDF document.https://www.rns-pdf.londonstockexchange.com/rns/1451R_1-2020-6-25.pdfThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactA rns@lseg.comA or visitA www.rns.com.Contacts:
RNS
Customer Services
0044-207797-4400
rns@londonstockexchange.com
https://www.rns.com
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2021    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728